GGrantIndex
← Leaderboards

Gregory B. Lesinski

Emory University

Google Scholar ↗PubMed ↗ORCID ↗
$9,344,242
Attributed
$13,450,362
Total exposure
16
Grants
13
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.2M · FY2008–25
$2.5M$1.9M$1.3M$625K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$13,450,362 · 16

By mechanism

R01$8,418,352 · 6
P30$1,976,769 · 1
R21$1,953,085 · 5
T32$635,639 · 1
K22$453,517 · 1
R13$13,000 · 2

Top collaborators

Most similar at Emory University

Same institution · by research overlap

Others in their field

Top investigators on “Immune”

Research focus

ImmuneCellsT-LymphocyteResponseMalignant NeoplasmsTumorCytokineSignal TransductionInterleukin-6Tumor MicroenvironmentInnovationImmunotherapyPhenotypePropertyClinical TrialsIn VitroPathway InteractionsPreclinical StudyBaseImmunityProgramsBiological MarkersFutureMediating

Grant awards (45)

Neoadjuvant SEMA4D/ICB therapy for melanoma$709,554
R01 · FY2025 · CA
Leveraging CD26high Meso-CAR T cells in patients with advanced pancreatic cancer$638,929
R01 · FY2025 · CA · contact PI
Shared Resource Management$258,889
P30 · FY2025 · CA · contact PI
Graduate Program in Cancer Biology Training at Emory University$199,361
T32 · FY2025 · CA · contact PI
Shared Resource Management$870,727
P30 · FY2024 · CA · contact PI
Leveraging CD26high Meso-CAR T cells in patients with advanced pancreatic cancer$575,241
R01 · FY2024 · CA · contact PI
Development of a PET CCR2 Imaging Agent to Profile PDAC Microenvironment$402,401
R21 · FY2024 · CA
Graduate Program in Cancer Biology Training at Emory University$221,904
T32 · FY2024 · CA · contact PI
Preoperative immunotherapy in Hepatocellular Carcinoma$173,764
R21 · FY2024 · CA · contact PI
Shared Resource Management$847,153
P30 · FY2023 · CA · contact PI
Targeting immune stroma interactions in pancreatic cancer$341,667
R01 · FY2023 · CA · contact PI
Preoperative immunotherapy in Hepatocellular Carcinoma$219,491
R21 · FY2023 · CA · contact PI
Graduate Program in Cancer Biology Training at Emory University$214,374
T32 · FY2023 · CA · contact PI
Modulation of the human pancreatic microenvironment by combined cytokine and immune checkpoint blockade$179,252
R21 · FY2023 · CA · contact PI
Targeting immune stroma interactions in pancreatic cancer$340,118
R01 · FY2022 · CA · contact PI
Modulation of the human pancreatic microenvironment by combined cytokine and immune checkpoint blockade$219,491
R21 · FY2022 · CA · contact PI
Targeted MEK inhibition to enhance immunotherapy in cholangiocarcinoma$412,434
R01 · FY2021 · CA · contact PI
Targeting immune stroma interactions in pancreatic cancer$345,477
R01 · FY2021 · CA · contact PI
Enhancing immune therapy in pancreatic cancer by targeting IL-6$303,623
R01 · FY2021 · CA · contact PI
Targeted MEK inhibition to enhance immunotherapy in cholangiocarcinoma$424,213
R01 · FY2020 · CA · contact PI
Targeting immune stroma interactions in pancreatic cancer$346,416
R01 · FY2020 · CA · contact PI
Enhancing immune therapy in pancreatic cancer by targeting IL-6$315,158
R01 · FY2020 · CA · contact PI
Targeted MEK inhibition to enhance immunotherapy in cholangiocarcinoma$390,583
R01 · FY2019 · CA · contact PI
Targeting immune stroma interactions in pancreatic cancer$343,355
R01 · FY2019 · CA · contact PI
Enhancing immune therapy in pancreatic cancer by targeting IL-6$309,956
R01 · FY2019 · CA · contact PI
Targeted MEK inhibition to enhance immunotherapy in cholangiocarcinoma$391,138
R01 · FY2018 · CA · contact PI
Enhancing immune therapy in pancreatic cancer by targeting IL-6$321,742
R01 · FY2018 · CA · contact PI
Modulation of antitumor immunity by dietary soy and its isoflavone constituents$319,549
R01 · FY2018 · CA
Stromal IL -6/Jak-STAT Signaling and Pancreatitis$144,704
R21 · FY2017 · AI
Stromal IL-6/Jak-STAT signaling and pancreatitis$23,100
R21 · FY2017 · AI
Modulation of antitumor immunity by dietary soy and its isoflavone constituents$1
R01 · FY2017 · CA
Modulation of antitumor immunity by dietary soy and its isoflavone constituents$319,550
R01 · FY2016 · CA · contact PI
Enhancing immune therapy in pancreatic cancer by targeting IL-6$300,300
R01 · FY2016 · CA · contact PI
Stromal IL-6/Jak-STAT signaling and pancreatitis$231,000
R21 · FY2016 · AI
Enhancing immune therapy in pancreatic cancer by targeting IL-6$21,489
R01 · FY2016 · CA · contact PI
Modulation of antitumor immunity by dietary soy and its isoflavone constituents$319,550
R01 · FY2015 · CA · contact PI
Translational Research Cancer Centers Consortium Annual Meeting$7,000
R13 · FY2015 · CA · contact PI
Modulation of antitumor immunity by dietary soy and its isoflavone constituents$309,796
R01 · FY2014 · CA · contact PI
Modulation of antitumor immunity by dietary soy and its isoflavone constituents$318,513
R01 · FY2013 · CA · contact PI
Translational Research Cancer Centers Consortium Annual Meeting$6,000
R13 · FY2012 · CA · contact PI
Evaluating the anti-tumor effects of novel curcumin analogs in melanoma$160,869
R21 · FY2011 · CA · contact PI
Evaluating the anti-tumor effects of novel curcumin analogs in melanoma$199,013
R21 · FY2010 · CA · contact PI
SOCS proteins as inhibitors of immune surveillance in the melanoma microenvironme$153,733
K22 · FY2010 · CA · contact PI
SOCS proteins as inhibitors of immune surveillance in the melanoma microenvironme$151,014
K22 · FY2009 · CA · contact PI
SOCS proteins as inhibitors of immune surveillance in the melanoma microenvironme$148,770
K22 · FY2008 · CA · contact PI